Daraxonrasib (Rasonque) Just Got FDA Approved — And It Might Not Stop at Pancreatic Cancer

On August 26, 2026, the FDA approved daraxonrasib, now marketed as Rasonque, for adults with metastatic pancreatic adenocarcinoma — landing roughly six and a half months ahead of the FDA's own review deadline. That's not just fast. It's the kind of speed that only happens when a clinical trial's data is unusually strong. If you or someone you love is navigating pancreatic cancer, here's what actually got approved, who qualifies, and why this particular targeted therapy could end up reaching far beyond pancreatic cancer treatment.

What got FDA approved

Rasonque is approved for adults with metastatic pancreatic adenocarcinoma who've already had at least one prior systemic therapy, or who aren't candidates for standard multi-agent chemotherapy. It's a once-daily oral tablet — no infusion chair required — taken until the disease progresses or side effects become unmanageable. In the trial behind this approval, median overall survival was roughly 13.2 months on daraxonrasib versus 6.7 months on chemotherapy alone. Because the trial only ran 20 months, a lot of patients hadn't hit their survival endpoint when the data was reported — which means real-world cancer experience may end up showing even stronger numbers over time.

Why this reaches so many more patients

This is the part worth getting excited about. Earlier RAS-pathway drugs only worked for patients with one specific KRAS mutation, which meant they reached a small slice of the pancreatic cancer population. Daraxonrasib works differently — it binds the active form of RAS itself, regardless of which exact mutation is driving it. That's why this approval covers the broader population of pancreatic cancer patients, not one narrow genetic subgroup.

The bigger picture: beyond pancreatic cancer

RAS mutations don't just drive pancreatic cancer — they're involved in a wide range of cancers, including many lung cancers. Because daraxonrasib targets the RAS pathway itself rather than one cancer type, it's already being tested in other cancers where RAS mutations show up. Today's pancreatic cancer approval will likely turn out to be the first of several, which is exactly why this drug is worth understanding now, even if pancreatic cancer isn't the cancer you're dealing with.

Cancer myths worth correcting

Some online claims have gone further than the data supports, suggesting KRAS testing is now pointless, or can cause problems. It isn't. Mutation status isn't a gatekeeper for this drug the way it was for earlier ones, but cancer research still shows some variation in response across different mutations — so knowing your profile helps set realistic expectations with your oncologist, and won't qualify or disqualify you.

What to do next

Bring Rasonque up with your oncology team today — you may need to ask for it by name. Any expanded-access programs closed the moment formal FDA approval came through, so access now runs only through standard prescribing. Ask your oncologist: Am I eligible based on my treatment history? Do we know my RAS pathway mutation status? And what does my plan look like now?

Accurate science saves lives — and it starts with rejecting simple myths in favor of real understanding. Stay curious.

Disclaimer:  This content is for educational purposes only and is not medical advice. It does not replace guidance from your healthcare provider. Cancer and treatment decisions are highly individual—always consult your physician or qualified healthcare professional regarding your specific situation.
A full disclaimer is available Terms and Conditions.